Eternity in Medical Information -- Medisurf
Search | Web Directory, News, Variable useful Information, PubMed In Medine, All
Category Select :
Items 1 ~ 20 of 3430, Page 1 of 173
1. Rising to the challenge of malaria eradication
08/23/2019 WHO
2. World Bank and WHO Statement on Partnership & Deployment of Financing to WHO for Ebola Response in DRC
08/22/2019 WHO
3. Three years without a case of wild polio virus, Government of Nigeria warns against complacency
08/21/2019 WHO
4. Burundi launches ebola vaccination campaign for health and front-line workers
08/14/2019 WHO
5. Merck Receives Positive EU CHMP Opinion for ZERBAXA® 3g Dose (ceftolozane and tazobactam) for the Treatment of Adults with Hospital-Acquired Pneumonia (HAP), Including Ventilator-Associated Pneumonia (VAP)
07/29/2019 MERCK
6. Merck Announces Presentation of Phase 2b Results for Investigational HIV-1 Therapy Islatravir (MK-8591) at IAS 2019
New Findings from Study Evaluating Islatravir in Combination with Doravirine versus DELSTRIGO™ (doravirine 100 mg/3TC 300 mg/tenofovir disoproxil fumarate 300 mg) / Company Plans to Initiate Phase 3 Trials
07/24/2019 MERCK
7. WHO applauds Rwanda’s Ebola preparedness efforts
07/24/2019 WHO
8. Merck Presents Early Evidence on Extended Delivery of Investigational Anti-HIV-1 Agent Islatravir (MK-8591) via Subdermal Implant
Phase 1 Data Presented Today at IAS 2019
07/23/2019 MERCK
9. WHO recommends dolutegravir as preferred HIV treatment option in all populations
07/22/2019 WHO
10. Ebola outbreak in the Democratic Republic of the Congo declared a Public Health Emergency of International Concern
07/17/2019 WHO
11. FDA Approves Merck’s RECARBRIO™ (imipenem, cilastatin, and relebactam) For the Treatment of Adults with Complicated Urinary Tract and Complicated Intra-Abdominal Bacterial Infections Where Limited or No Alternative Treatment Options Are Available
07/17/2019 MERCK
12. 20 million children miss out on lifesaving measles, diphtheria and tetanus vaccines in 2018
07/15/2019 WHO
13. High-level meeting on the Ebola outbreak in the Democratic Republic of the Congo affirms support for Government-led response and UN system-wide approach
07/15/2019 WHO
14. Merck Highlights Commitment to HIV Research with Presentations for Investigational Anti-HIV Agent MK-8591 at IAS 2019
Data Include Week 48 Results from Phase 2B Study Evaluating MK-8591 in Combination with Doravirine
07/10/2019 MERCK
15. WHO updates global guidance on medicines and diagnostic tests to address health challenges, prioritize highly effective therapeutics, and improve affordable access
New essential medicines and diagnostics lists published today
07/09/2019 WHO
16. More than a million people to be vaccinated in phase 2 of a huge cholera vaccination campaign in the Democratic Republic of the Congo
07/03/2019 WHO
17. Eliminating trachoma: WHO announces sustained progress with hundreds of millions of people no longer at risk of infection
The number of people at risk of trachoma ?the world뭩 leading infectious cause of blindness ?has fallen from 1.5 billion in 2002 to just over 142 million in 2019, a reduction of 91%, WHO has reported.
06/27/2019 WHO
18. CDC Advisory Committee on Immunization Practices (ACIP) Votes to Provisionally Recommend Shared Clinical Decision-Making for Vaccination of Adults Ages 27-45 with GARDASIL®9 & Harmonization of Catch-up Vaccination for Males and Females Through Age 26
06/26/2019 MERCK
19. WHO flags critical funding gap, calls for political parties to join fight against Ebola
WHO Director-General briefs Members States on situation in DRC and appeals for funding for the Ebola response
06/19/2019 WHO
20. In the face of slow progress, WHO offers a new tool and sets a target to accelerate action against antimicrobial resistance
06/18/2019 WHO
   
1 2 3 4 5 6 7 8 9 10
 
경기도 성남시 분당구 구미동 25-1 엘레강스 프라자 ㈜ 메디서프 | Tel : 031-896-0930 | 사업자 등록번호 : 212-81-47247
통신판매신호번호 : 경기 성남 2007-712 | 대표이사 한상욱